Along with a couple hundred healthcare association executives, I had the pleasure of attending the ASAE Healthcare Association Conference on November 18-19, 2010, here in Chicago.
We had a great four days at the Professional Convention Management Association (PCMA) Annual Meeting this week. The event’s host city, Dallas, repeated its catchy “One More Thing” theme throughout the event. With my thanks to Dallas for a great job as host, here are eight more observations from PCMA—I promise at least seven of them have real-life applications, and I’ll let you decide about #8. more
I'm co-facilitating two interactive sessions next week at the PCMA Annual Meeting: (1) a roundtable discussion about industry funding for medical meetings and (2) a panel on how to get (and think about) sponsorships of meetings, associations and destinations. (For more information, including the schedule, check out www.pcma2010.org.) more
Senator Charles Grassley (R-Iowa) has made it a personal mission to uncover [questionable] relationships between non-profit healthcare groups and pharmaceutical and medical device companies, ostensibly to prevent any censored or conflicted information from making its way into or out of the organizations we trust. This week, 33 more organizations received their "Grassley letters," following in the long line of sigh-inducing paperwork that has ramped up since last fall. more
Cancer.net Skate America begins today in Lake Placid, N.Y., marking a significant development in sponsorship. The title sponsor is the consumer Web site of the American Society of Clinical Oncology, a physician’s membership association.
The professional organization is paying a cash fee to U.S. Figure Skating, and told IEG Sponsorship Report last month that this will not be its last sponsorship. “Doing this once is not going to be sufficient. We’re in the process of talking to other organizations,” said Allen Lichter, MD, the association’s CEO. more
Dizziness? Fainting? Numbness in the extremities?
These are child's play compared to the pictures painted by some concerned healthcare industry colleagues yesterday afternoon at an event put on by the Association Forum of Chicagoland. The topic of the event was the codes of ethics and regulations the healthcare industry is implementing that govern activities of companies, healthcare practitioners and the organizations and institutions that represent them.
I get a fair number of questions about “sponsorship models”—as in, which sponsorship model will work for my organization or company?
Frankly, I bristle at this, as it is the strategic equivalent to handing out oversized oven mitts to do the dishes, when only custom-sized rubber gloves will do.
Thus, in this post, I’m speaking to how each property’s unique culture impacts strategy creation. In my next post, I’ll speak to how culture comes in to play for sponsors’ buying strategies.
Per a recent request of a couple of medical society CEOs, I am posting the letter we submitted to the Journal of the American Medical Association (JAMA) Editor back in April 2009. JAMA did not publish it, and I’ve been asked to make it available to the community. Would love to hear your thoughts. more
A recent article entitled “Spoonfuls of sponsorship making medical students sick” from The Age in Australia (thanks for forwarding, Lesa) talks about medical students who have pledged to immunize themselves from all pharma marketing—not only rejecting free pens and tchotchkes (which were essentially taken off the table in the US this year via voluntary ethics codes from PhRMA and AdvaMed) but also swearing off any forms of industry-sponsored education.
These Aussie MDs-to-be are not necessarily blazing trails with this pledge; indeed there are codes and suggestions from industry groups in the U.S. right now that recommend similar measures.
From one perspective, we should admire healthcare professionals, and the organizations that represent them, for attempting to clean up their conflicts of interest. But from another perspective, do these efforts to restrict represent a slippery slope that could end with unintended consequences? While building firewalls to prevent impropriety, might we end up building silos and barriers to life-saving communication? And could educational and research funding dry up, resulting in less of both? more
I listen to so much discourse about the evolution of sponsorship and how it has—and has not—come into its own. From a [official] status symbol to an agent of [financial, societal, experiential] change, the medium continues to mature to reflect the thinking of a new day.
Yet, in years, sponsorship is a relatively immature medium, so what do we want sponsorship to be when it grows up? Should we worry that it will lose its youthful energy? Or do we look forward to the day when it puts away childish things, such as those elements that allow sponsor and property a moment of shared swagger but drive no value for the audience?
I am working with groups and companies in a number of sponsorship sectors right now that are actively, vocally trying to figure out what's next. more